ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
Christian Dittrich(Kaiser-Franz-Josef-Spital), Rainer Kunstfeld(Vienna General Hospital), Roisín M. Connolly(Johns Hopkins University), Jørn Herrstedt(Zealand University Hospital), Ahmad Awada(Institut Jules Bordet), Christian Herold(Vienna General Hospital), Julia Close(University of Florida), Jean‐Pierre Lotz, Jennifer M. Duff(University of Florida), Alexander Kiss(University Hospital of Basel), Rossana Berardi(Marche Polytechnic University), Priya Gopalan(University of Florida), Fátima Cardoso(Université Paris Cité), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Dennie V. Jones(University of Florida), Sarah E. Coupland(University of Liverpool), Jan C. Buckner(McGill University), Andor W.J.M. Glaudemans(Boston University), Don S. Dizon(Harvard University), Smita Bhatia(University of Alabama at Birmingham), Krisztián Homicskó(University Hospital of Lausanne), Linda Duska(University of Virginia), Axel Grothey(Mayo Clinic in Arizona), Luigi De Petris(Karolinska University Hospital), Alexandru Eniu(Institute of Oncology Prof. Dr. Ion Chiricuta), Elisabeth G.E. de Vries(University Medical Center Groningen), Pia Österlund(University of Helsinki), Nicholas Pavlidis(University of Ioannina), Susana Banerjee(Royal Marsden NHS Foundation Trust), Ulrich Keilholz(Berliner Hochschule für Technik), Jonas Bergh(Karolinska University Hospital), Jan Bogaerts(European Organisation for Research and Treatment of Cancer), Edward Chu(UPMC Hillman Cancer Center), Michael P. Kosty(Scripps Green Hospital), Marc S. Ernstoff(Roswell Park Comprehensive Cancer Center), Enriqueta Felip(Universitat Autònoma de Barcelona), Nicolas Girard(Memorial Sloan Kettering Cancer Center), Saad A. Khan(Southwestern Medical Center), Maria De Santis(Medical University of Vienna), Diana L. Hanna(University of Southern California), Doug Pyle(American Society of Clinical Oncology), Jill Gilbert(Cancer Clinic), Nagi S. El-Saghir(American University of Beirut Medical Center), Stephen M. Hahn(The University of Texas MD Anderson Cancer Center), Martin F. Fey(European Union), Claus-Henning Köhne(Klinikum Oldenburg), S. Jezdic(European Society for Medical Oncology), Gunta Purkalne(Pauls Stradiņš Clinical University Hospital), Lorenz Jost(Kantonsspital Baselland Standort Bruderholz), Bertrand Coiffier(Hospices Civils de Lyon)
Cited by 129
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Photodynamic therapy of cancer: An update
|CA A Cancer Journal for Clinicians|2011|5.1k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k